Latest Research And Development News

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

Recce Pharmaceuticals has secured a second Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to test its RECCE 327 Gel in burn wound infection models, underscoring growing military interest in its synthetic anti-infectives.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

Matsa Resources reported solid progress at its Lake Carey Gold Project, delivering $11.73 million in gold sales and initiating new exploration drilling to boost its resource base.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

BPH Global has reported record sales in its Indonesian seaweed operations alongside completing a $1.1 million capital raise and advancing promising R&D projects. The company is scaling its trading platform and expanding into bio-stimulants and wellness products as it enters 2026.

Redstone Resources has reported significant new high-grade copper intersections at unprecedented depths beneath its Tollu Copper deposit in Western Australia, hinting at a larger magmatic sulphide system. The company also secured government grants and raised capital to advance exploration.

InFocus Group Holdings Limited has formalised its strategic expansion into iGaming and digital assets, appointing a high-profile advisory board and strengthening its capital position through convertible notes and Bitcoin ETF investments.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.

Talga Group has reported a quarter of significant commercial and regulatory progress, including its largest anode shipment, expanded product offerings, and major mining approvals in Sweden, supported by substantial capital raises and new patents.

Tissue Repair’s December quarter update reveals a cautious path forward for its Phase 3 TR987 trial amid slow patient recruitment, while its TR Pro+ product line gains momentum through a new distributor partnership and upcoming product launches.